The object of the present invention are new, reduced dosage, solid or liquid formulations based on amisulpride or pharmaceutically acceptable salts or derivatives thereof, and the use of the aforementioned formulations in the treatment of major depression and/or dysthymia; in particular, the formulations of the present invention have the peculiarity of allowing a lower dosage of the active principle compared to the formulations known in the art, thus making it adjustable according to the specific characteristics of the patient.
展开▼
